Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine +/- Cyclophosphamide in Stage IV Melanoma
NCT00722098Phase 2
Key facts
- Status
- Terminated
- Start
- Jun 2008
- Primary completion
- Apr 2011
- Countries
- 1
- Sponsor
- Baylor Scott & White Research Institute
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Conditions
- Malignant Melanoma (MM)
01
Overview
Phase 2, randomised, double-blind trial of Dendritic cell vaccine (Mackay Memorial Hospital) in Malignant Melanoma (MM), sponsored by Baylor Scott & White Research Institute. Started Jun 2008; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
HLA-A*0201 positive patients with Stage IV melanoma, ECOG 0-1, and no active CNS disease.
04
Registry description
The purpose of this study is to determine whether the combination of chemotherapy (Cyclophosphamide) and CD34-DC vaccines results in the improved rate of clinical responses for stage IV melanoma patients.
Beyond the preview
Go deeper on NCT00722098.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00722098.